These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Chong SY; Egan MA; Kutzler MA; Megati S; Masood A; Roopchard V; Garcia-Hand D; Montefiori DC; Quiroz J; Rosati M; Schadeck EB; Boyer JD; Pavlakis GN; Weiner DB; Sidhu M; Eldridge JH; Israel ZR Vaccine; 2007 Jun; 25(26):4967-82. PubMed ID: 17335943 [TBL] [Abstract][Full Text] [Related]
24. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus. Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703 [TBL] [Abstract][Full Text] [Related]
25. Adenoviruses as vectors for HIV vaccines. Gómez-Román VR; Robert-Guroff M AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567 [TBL] [Abstract][Full Text] [Related]
26. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase. Suh YS; Park KS; Sauermann U; Kim KS; Ahn SS; Franz M; Schulte R; Wilfingseder D; Stoiber H; Uberla K; Hunsmann G; Stahl-Hennig C; Sung YC Vaccine; 2008 Dec; 26(51):6690-8. PubMed ID: 18694796 [TBL] [Abstract][Full Text] [Related]
27. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199 [TBL] [Abstract][Full Text] [Related]
28. Phenotypic and kinetic analysis of effective simian-human immunodeficiency virus-specific T cell responses in DNA--and fowlpox virus-vaccinated macaques. Stratov I; Dale CJ; Kent SJ Virology; 2005 Jul; 337(2):222-34. PubMed ID: 15907968 [TBL] [Abstract][Full Text] [Related]
29. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. Schulte R; Suh YS; Sauermann U; Ochieng W; Sopper S; Kim KS; Ahn SS; Park KS; Stolte-Leeb N; Hunsmann G; Sung YC; Stahl-Hennig C Virology; 2009 Jan; 383(2):300-9. PubMed ID: 19027133 [TBL] [Abstract][Full Text] [Related]
30. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586 [TBL] [Abstract][Full Text] [Related]
31. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560 [TBL] [Abstract][Full Text] [Related]
32. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746 [TBL] [Abstract][Full Text] [Related]
33. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Sasaki S; Tsuji T; Asakura Y; Fukushima J; Okuda K Anticancer Res; 1998; 18(5D):3907-15. PubMed ID: 9854503 [TBL] [Abstract][Full Text] [Related]
34. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317 [TBL] [Abstract][Full Text] [Related]
35. Candidate vaccines protect macaques against primate immunodeficiency viruses. Stott J; Hu SL; Almond N AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S265-70. PubMed ID: 9814954 [TBL] [Abstract][Full Text] [Related]
36. Worldwide survey of AIDS vaccine challenge studies in nonhuman primates: vaccines associated with active and passive immune protection from live virus challenge. Warren JT; Dolatshahi M J Med Primatol; 1992; 21(2-3):139-86. PubMed ID: 1433265 [TBL] [Abstract][Full Text] [Related]
37. [Brief history of AIDS in non-human primates and its contribution to the study of acquired immunodeficiency syndrome]. Málaga CA; Kraiselburd E; Lavergne JA; Del Llano AM; Amieiro JP P R Health Sci J; 1993 Apr; 12(1):47-54. PubMed ID: 8511246 [TBL] [Abstract][Full Text] [Related]
39. AIDS vaccines: concepts and first trials. Sonigo P; Montagnier L; Tiollais P; Girard M Immunodefic Rev; 1989; 1(4):349-66. PubMed ID: 2698645 [TBL] [Abstract][Full Text] [Related]
40. The development of an AIDS vaccine: progress and promise. Fauci AS; Fischinger PJ Public Health Rep; 1988; 103(3):230-6. PubMed ID: 3131812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]